BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36464833)

  • 21. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma.
    Kobayashi A; Sakuma T; Fujimoto M; Jimbo N; Hirose T
    Appl Immunohistochem Mol Morphol; 2019; 27(10):758-763. PubMed ID: 31145104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.
    Keung EZ; Hornick JL; Bertagnolli MM; Baldini EH; Raut CP
    J Am Coll Surg; 2014 Feb; 218(2):206-17. PubMed ID: 24315890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review.
    Assi T; Kattan J; Rassy E; Nassereddine H; Farhat F; Honore C; Le Cesne A; Adam J; Mir O
    Crit Rev Oncol Hematol; 2020 Sep; 153():103029. PubMed ID: 32593094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
    Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D; Van Gorp J; Speel EJ; Ferdinande L
    Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dedifferentiated liposarcoma with homologous lipoblastic differentiation: expanding the spectrum to include low-grade tumours.
    Liau JY; Lee JC; Wu CT; Kuo KT; Huang HY; Liang CW
    Histopathology; 2013 Apr; 62(5):702-10. PubMed ID: 23425231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Characterization of a Rare Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation in a 24 Year Old.
    Olson N; Gularte-Mérida R; Selenica P; Da Cruz Paula A; Alemar B; Weigelt B; Lefferts J; Linos K
    Int J Surg Pathol; 2020 Jun; 28(4):454-463. PubMed ID: 31801397
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
    Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of age and subtype in outcome of operable liposarcoma.
    Greto D; Saieva C; Loi M; Terziani F; Visani L; Garlatti P; Lo Russo M; Muntoni C; Becherini C; Topulli J; Campanacci D; Beltrami G; Scoccianti G; Muratori F; Bonomo P; Desideri I; Francolini G; Livi L
    Radiol Med; 2019 Apr; 124(4):290-300. PubMed ID: 30421387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
    Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
    Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
    Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
    Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma.
    Horvai AE; DeVries S; Roy R; O'Donnell RJ; Waldman F
    Mod Pathol; 2009 Nov; 22(11):1477-88. PubMed ID: 19734852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report.
    Grifasi C; Calogero A; Carlomagno N; Campione S; D'Armiento FP; Renda A
    World J Surg Oncol; 2013 Nov; 11():305. PubMed ID: 24279301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Well-differentiated and dedifferentiated liposarcomas.
    Coindre JM; Pédeutour F; Aurias A
    Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dedifferentiated Liposarcoma With Epithelioid/Epithelial Features.
    Makise N; Yoshida A; Komiyama M; Nakatani F; Yonemori K; Kawai A; Fukayama M; Hiraoka N
    Am J Surg Pathol; 2017 Nov; 41(11):1523-1531. PubMed ID: 28719466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.
    Amin-Mansour A; George S; Sioletic S; Carter SL; Rosenberg M; Taylor-Weiner A; Stewart C; Chevalier A; Seepo S; Tracy A; Getz G; Hornick JL; Nucci MR; Quade B; Demetri GD; Raut CP; Garraway LA; Van Allen EM; Wagner AJ
    Clin Cancer Res; 2019 Aug; 25(16):5135-5142. PubMed ID: 31164371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
    Przybyl J; Spans L; Ganjoo K; Bui N; Mohler D; Norton J; Poultsides G; Debiec-Rychter M; van de Rijn M
    PLoS One; 2022; 17(1):e0262272. PubMed ID: 34986184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.